Entera Bio, a large-molecule drug spinout of DNA Biomedical Solutions, intends to raise up to $50m when it goes public.
Entera Bio, an Israel-based large-molecule therapeutics developer spun out of drug-delivery technology provider DNA Biomedical Solutions, has filed to raise up to $50m in an initial public offering in the US.
Entera is working on large-molecule drugs that will target orphan conditions and those with significant unmet medical need.
The company’s lead product candidate, EB612, is an oral formulation of a hormone called PTH that will treat hypoparathyroidism, a condition where insufficient PTH is produced by the body.
The IPO…
